VVMF Capabilities
Your end-to-end viral vector CDMO partner
VVMF supports viral vector programs across the full development lifecycle, from discovery and R&D to late-stage development, clinical manufacturing, and commercial supply.
Our service roadmap provides the right expertise, technologies, and manufacturing solutions at each stage, helping clients move forward with speed, flexibility and confidence.
End-to-end viral vector CDMO capabilities
From vector design to GMP manufacture and release, VVMF supports viral vector programs with integrated scientific, process, manufacturing, and quality capabilities
R&D and Vector Candidate Discovery
Early-stage support for vector design, plasmid sourcing, and cell banking, helping clients select and prepare candidates with manufacturability, performance, and clinical translation in mind.
Process and Analytical Development
Scalable process development, analytical methods, Quality by Design, and Design of Experiments approaches to build process understanding, improve performance, and support GMP readiness.
Industrialisation and Manufacturing
Flexible manufacturing and fill-finish solutions designed to translate development processes into reliable, traceable, and phase-appropriate GMP production.
Quality Control and Assurance
Comprehensive QC testing, release documentation, and quality oversight to support regulatory confidence and clinical or commercial material supply.
Our Key Services
Vector Design
Clinical construct design, serotype or pseudo type selection, tropism assessment, and gene-of-interest optimisation to support target application and manufacturability.
Plasmids Sourcing
High-quality plasmid design, construction, and GMP-grade sourcing to support traceable, reliable, and performance-ready vector production.
Cell Banking
Master and working cell bank generation with full characterisation and regulatory documentation to support development and GMP manufacturing readiness.
Process Development
Scalable upstream and downstream process development using platform-based approaches across research, toxicology, and GMP-enabling production stages.
Analytics
Comprehensive analytical method development, qualification, and validation to support process understanding, product characterisation, and release readiness.
Quality by Design Approach
Quality by Design and Design of Experiments methodologies to systematically optimise processes, define critical parameters, and strengthen control strategies.
Drug Substance Manufacturing
GMP drug substance manufacturing from development to production scale, with full batch documentation, traceability, and phase-appropriate controls.
Drug Product Manufacturing
Flexible formulation, filling, and finishing solutions delivered through internal capabilities and trusted partners to support clinical and commercial supply needs.
QC Testing and Release
Complete quality control testing, release documentation, and regulatory-compliant certificates of analysis to support material use and product progression.
AAV and LV vector platforms to make viral vector manufacturing faster, more robust and cost-effective.
As viral vector-based therapies expand into cancer, chronic disease, and autoimmune indications, developers need faster, simpler pathways from development through to scalable manufacturing. VVMF supports this need through platformised, ready-to-use solutions that integrate upstream production, downstream purification, quality control, and analytical testing.
Built around optimized HEK-293 suspension cell systems, our transient expression platforms are designed to reduce development complexity, shorten production lead times, and improve manufacturing consistency. With only targeted process fine-tuning required, clients can lock processes faster and scale production more efficiently.
Adeno-Associated Virus (AAV)
Scalable AAV production using optimised HEK-293 suspension systems up to 500L, transient triple or dual transfection, platform purification based on affinity and ion exchange chromatography, and integrated analytics to accelerate development and GMP translation.
Lentivirus (LV)
Robust VSV-G lentiviral vector production through scalable HEK-293 suspension workflows, optimised upstream up to various bioreactor volumes, downstream processing, and phase-appropriate analytical control designed for ex-vivo CAR-T applications.
Bespoke
For products with unique requirements, VVMF applies its platform knowledge, development toolbox, and analytical capabilities to design and optimise tailored manufacturing solutions.
When a product does not fit a standard platform workflow, VVMF applies its bioprocessing toolbox to build a tailored development path.
Our bespoke services can support construct or vector-specific requirements across upstream processing, downstream purification, analytics, formulation, scale-up, technology transfer and GMP readiness.
This allows clients to retain the speed and structure of VVMF’s platform knowledge while addressing the specific needs of their therapy.
Our Facilities
Facilities built for every stage of viral vector development
Our facilities are designed to support viral vector programs with flexibility, consistency, and scale.
Dedicated development facilities to support versatile needs from small scale R&D requirements to 50L Toxicology material production
State of the art analytical laboratories with capabilities in characterisation, in-process testing and quality control
Small-scale and large-scale GMP manufacturing capacity to support a range of vector needs from pre-clinical and early clinical to clinical manufacturing and technology transfer
Development
Comprehensive R&D, process development and analytical capabilities, supporting non-GMP production up to 50 L, including material for toxicology studies and late-stage development activities.
Small Scale Manufacturing
Flexible 1L to 25L GMP manufacturing with rocking motion or stirred-tank bioreactor options, low hold-up downstream processing for early lifecycle batches and low vector demand programs.
Large Scale Manufacturing
Scalable 50 L, 200 L and 500 L GMP manufacturing with dedicated LV and AAV suites, FlexFactory™ single-use technology and versatile downstream processing for clinical manufacturing and technology transfer.
Drug Product Manufacturing
Semi-automated fill finish line with 2mL and 10mL borosilicate glass vials and capacity up to 1,000 vials per batch.
The Australian Advantage
Why Australia is the strategic choice for emerging biopharma
Frequently Asked Questions
What does VVMF specialise in?
VVMF specialises in Adeno-Associated Virus (AAV) and lentiviral (LV) vector development and manufacturing, supporting advanced therapy programs from early development through to GMP production.
Which stages of development can VVMF support?
We support the full viral vector lifecycle, from discovery, R&D, and process development to clinical manufacturing and commercial supply readiness.
What manufacturing capacity does VVMF offer?
VVMF offers small-scale GMP manufacturing from 1 L to 25 L and large-scale GMP manufacturing at 50 L, 200 L and 500 L bioreactor capacities.
Does VVMF offer non-GMP development material?
Yes. Our development facility supports process and analytical development, including non-GMP production up to 50 L for late-stage development and toxicology material.
What technology platforms does VVMF use?
VVMF uses modern, fully single-use manufacturing technologies, platformised AAV and LV workflows, and flexible downstream processing to support development, scale-up and GMP manufacture.
Can VVMF support bespoke development needs?
Yes. Where a product requires a tailored approach, VVMF applies its process development toolbox, analytics and platform knowledge to design fit-for-purpose manufacturing solutions.
How does VVMF support quality and release?
VVMF integrates QC testing, analytical methods, release documentation and quality oversight to support material readiness and regulatory confidence.
What makes VVMF’s team distinctive?
Our team brings deep viral vector expertise, strong links to Australia’s advanced therapies ecosystem and a committed, collaborative approach to client delivery.
Why manufacture in Australia?
Australia offers a strong clinical research ecosystem, Asia Pacific region access and potential R&D Tax Incentive benefits for eligible activities.
Can VVMF help international clients?
Yes. VVMF is positioned to support Australian and international biopharma clients seeking an integrated viral vector development and manufacturing pathway in Australia.